Table 3.
Adjusted risk of severe CAC according to the presence or absence of MASLD or MAFLD.
| Number | Severe CAC | Model 1 aOR (95% CI) |
Model 2 aOR (95% CI) |
Model 3† aOR (95% CI) |
|
|---|---|---|---|---|---|
| MASLD | |||||
| No-MASLD | 1868 | 115 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| MASLD | 905 | 81 | 1.60 (1.16–2.22)* | 1.49 (1.07–2.08)* | 1.38 (1.01–1.89)* |
| MAFLD | |||||
| No-MAFLD | 1520 | 86 | 1 (ref.) | 1 (ref.) | 1 (ref.) |
| MAFLD | 1253 | 110 | 1.49 (1.10–2.03)* | 1.33 (0.97–1.82) | 1.15 (0.84–1.57) |
*A p-value < 0.05. Model 1, adjusted for age and sex; Model 2, Model 1 + smoking, use of statins, diabetes, and advanced fibrosis; Model 3: †ASCVD risk score. Presence of severe CAC is defined as a CAC score > 300 and advanced fibrosis is defined as a fibrosis-4 index ≥ 2.67. †The ASCVD risk score includes age, sex, race, smoking status, blood pressure, medication use for hypertension, diabetes status, total cholesterol, and high-density lipoprotein cholesterol. CAC coronary artery calcification, MASLD metabolic dysfunction-associated steatotic liver disease, MAFLD metabolic dysfunction-associated fatty liver disease, aOR adjusted odds ratio, CI confidence interval, ref. reference, ASCVD atherosclerotic cardiovascular disease.